

Inclisiran Implementation Action Tracker

Last review: 27/03/2023

Today's date: 19/04/2023

TIPS FOR USING THE TRACKER

1. Ensure that you are using an accurate ID number and not duplicating one that may have already been used.
2. Ensure that you have filled out columns B, D, G, H, I, L and R (as a minimum)
3. Once an action is closed, mark this in column K
4. When searching actions assigned to a meeting, do this using column R, 'New Governance Group', so that any legacy actions are pulled through

ID	MEETING / DOCUMENT	DATE	OWNER	DELIVERABLE / ACTION	DEADLINE	STATUS	NOTES
A0191	Lipid Management Programme Board meeting	08/07/22	MR / GF / JN	To refine the agenda for LMPB into 2 parts with BPO Leads to contributing with agenda items for BPO part	12/08/2022	Closed	Agenda will consist of 2 parts – first part NV5 to be included. BPO will be responsible for their parts of the agenda but should be present in the entire meeting as there is significant overlap with both groups
A0192	Lipid Management Programme Board meeting	08/07/22	MR	Ensure that recognition of progress made is included as a key element of the terms of this meeting so that they are fed into JSC	12/08/2022	Closed	
A0193	Lipid Management Programme Board meeting	08/07/22	MR	To remove the box containing "Legacy meetings" as currently there are no legacy meetings in the governance structure	12/08/2022	Closed	
A0194	Lipid Management Programme Board meeting	08/07/22	MR / GF / JN / PJ	To discuss & agree on the functionality of CLOG	12/08/2022	Closed	To define a need for ongoing interaction of the CLOG members eg as a CoP for shared best practice and to receive performance updates.
A0195	Lipid Management Programme Board meeting	08/07/22	MR / GF	If possible, to reduce the LMPB to 15 to 20 members	12/08/2022	Closed	To ensure we have line of sight of critical members
A0196	Lipid Management Programme Board meeting	08/07/22	GF / JN / KW	Circulate for group to review (suggestion amendments and addition)		Closed	
A0197	Lipid Management Programme Board meeting	08/07/22	NA	To discuss the cost associated with SPIRIT	12/08/2022	Closed	NA to own an agenda item (10 minutes) at the next LMPB to discuss SPIRIT
A0198	Lipid Management Programme Board meeting	08/07/22	JS / JT	To clarify if appropriate for information and data around PCSK9i be shared at the LMPB	12/08/2022	Closed	If there are any commercial sensitivities around the PCSK9i uptake data, the agenda will be divided into two sections where competing industry partners are not present.
A0199	Lipid Management Programme Board meeting	08/07/22	LC / JS	Discuss if treatment adherence and LDLC outcomes can be included in the data and metrics. Ensure a breakdown of AHSN level uptake of all therapies is provided to the LMPB.	12/08/2022	Closed	Treatment adherence is already included in the primary care data but is not possible in secondary care because the data does not include patient identifiers. Although, when a GP prescribes multiple vials for a patient on a single prescription then adherence monitoring becomes less useful because the other doses are held by the GP. GP data is needed to monitor cholesterol levels and also if you want see the combination with adherence. Cholesterol levels and treatment adherence are not centrally collected for secondary care.
A0310	Lipid Management Programme Board meeting	08/07/22	KW	Further LMPB meetings to be divided into 2 parts (2 meeting invites); 1st invite to include NV5 members, 2nd invite to be sent to exclude external members	01/09/2022	Closed	As previously agreed, further LMPB meetings will be divided into two parts due to commercial sensitivity and relevance. KW to create and own two separate LMPB meetings going forward. Every third meeting of the LMPB will consider the wider AHSN work on lipid management (e.g. BP and FH), through a part 2 to the meeting with an extended membership (excluding external partners). There may also need to be part 2 discussion to the monthly meetings, where external partners are asked to leave, where there is an identified conflict of interest.
A0311	Lipid Management Programme Board meeting	12/08/22	NA	To inform the Programme on how the learnings from the SPIRIT study are being used to accelerate uptake in primary care	01/09/2022	Closed	NA to share the final report and present if needed. Content to be shared to this group, clinical leaders group, and JSC
A0312	Lipid Management Programme Board meeting	12/08/22	MR	To provide membership lists of all meetings which sit above LMPB to MS	26/08/2022	Closed	Funding issues to be escalated to JSC
A0313	Lipid Management Programme Board meeting	12/08/22	MR / KW	To request JSC course of action for when the commercial agreement expires	01/09/22	Closed	21/11 - Part of Pricing T&F group and included within FAQ section of new Funding and Supply Document 26/ 08 - Added joint ownership with KW
A0314	Lipid Management Programme Board meeting	12/08/22	MR	To update risk register: - Help needed from AHSN colleagues around FH (JC / NU); - Risk around payment issues for inclisiran to be added; and - Risk in relation to a potential delay to signing the Collaborative Working Agreement to be added (noting impact on the go-live for the STF and Third Party Suppliers work)	01/09/2022	Closed	25/08 - Risk register updated and reviewed
A0315	Lipid Management Programme Board meeting	12/08/22	MR	To escalate discussions around Collective Working Agreement to the JSC	05/09/2022	Closed	26/08 - Added to agenda for JSC 5 Sept
A0316	Lipid Management Programme Board meeting	12/08/22	SC / DM	Membership for Delivery Models T&F Group to be brought up to LMPB for review	01/09/2022	Closed	23/08 - Revised deadline to reflect new meeting date
A0317	Lipid Management Programme Board meeting	12/08/22	LC / JS/ MS	Metrics and Reporting to be brought out to September LMPB	30/08/2022	Closed	LC, JS and MS to discuss whether a joined up approach on metrics & reporting might be beneficial.
A0318	Lipid Management Programme Board meeting	12/08/22	SC / NU	Provide more detail around secondary care data relating to inclisiran	30/08/2022	Closed	Also, to provide detail around the early success of implementation in West of England; how do we replicate that in other 13 AHSNs?
A0319	Lipid Management Programme Board meeting	12/08/22	JC	To provide more robust data around Lipid optimisation & FH, and FH only	30/08/2022	Closed	JC conducting one to one AHSN support meetings reviewing stages of adoption to enhance better uptake and achievement of programme trajectories. Use the last Q1 (2022/23) AHSN level performance data to reiterate the relationship between better pathway adoption by GP practices and achievement of set quarterly trajectories. Support sessions with the 15 AHSN lipid leads all organised.
A0393	Lipid Management Programme Board meeting	09/09/22	AS / NA	PW to attend appropriate groups/meetings to provide overview on SPIRIT Early Insights Report	01/10/2022	Closed	
A0394	Lipid Management Programme Board meeting	09/09/22	KW	Update Terms of Reference to reflect new structure and quarterly BPO meeting	14/10/2022	Closed	
A0395	Lipid Management Programme Board meeting	09/09/22	LC	Confirm that dashboard can be hosted on FuturesNHS and if there is any sensitivity around publicly available data	14/10/2022	Closed	05/10 - Dashboard now live on Futures as interim platform until more suitable option is decided on
A0396	Lipid Management Programme Board meeting	09/09/22	SR	SR to submit formal patient engagement paper to LMPB for review	11/11/22	Closed	26/01 - Shared as part of LMPB agenda today 08/12 – Confirm if still required, following confirmation from ET 11/11 - MR to Follow-up with SR for update on patient engagement
A0397	Lipid Management Programme Board meeting	09/09/22	ET	Confirmation required as to whether a patient representative can attend LMPB moving forwards	30/09/22	Closed	08/12 - MR confirmed that ET has provided formal confirmation 11/11 - Aligned on LMPB being owned by AHSN, need to ensure there are clear parts of the meeting where external stakeholders are excluded
A0439	Lipid Management Programme Board meeting	14/10/22	SC / NU	Pathway Dissemination - Confirm w/AHSN comms team for Pathways to be uploaded to AHSN Network websites w/c 17 Oct	11/11/22	Closed	14/10 - Noted that Novartis colleagues can access and are welcome to utilise uploaded content on AHSN Network & Heart UK as this is in the public domain (i.e. is open access content)
A0440	Lipid Management Programme Board meeting	14/10/22	JP / SR	JP and SR to review animation and patient information leaflet and feedback to GF (and LMPB)	11/11/22	Closed	03/03 - Completed, initial animations and leaflets completed and comms colleagues taking forward plan for dissemination. Here are links to current resources and the comms plan Leaflets - https://www.heartuk.org.uk/cholesterol/booklets Animations - https://youtube.com/playlist?list=PLSNVkh3ksjmulwL65QJ2DYtjgchYSRX 31/01 - Pending update from SR 09/12 - JP send SR feedback 08/12 – Clarify next steps for materials: where will they be posted and who will be delivering. Suggestion for Sian to join comms working group within Clinical Pathways T&F group 11/11 - Meeting with SR scheduled for December

A0441	Lipid Management Programme Board meeting	14/10/22	MR	Understanding Health Inequalities - Gain understanding on what intelligence we hold on Lipid Management data against CVD (cholesterol) data. Explore the ability to compare data on the use of LLTs against HI demographic data	11/11/22	Closed	11/11 - Action to be closed as it fits with action A0450 and work on Metrics T&F Group.
A0442	Lipid Management Programme Board meeting	14/10/22	SC / DM / NU	Produce a comparison of formulary statuses of Inclisiran vs. Bemp Acid	11/11/2022	Closed	Closing action to instead reframe as decision
A0443	Lipid Management Programme Board meeting	14/10/22	NA	NA, GF, MR, and SC to discuss further work around the ARC study. Meeting to occur ahead of next JSC	28/10/22	Closed	11/11 - Action to be closed
A0444	Lipid Management Programme Board meeting	14/10/22	JP / SR	Pathway dissemination - include Pathways in Heart UK HCP (sent w/c 17 Oct)	19/10/22	Closed	11/11 - Action to be closed
A0445	Lipid Management Programme Board meeting	14/10/22	DECISION	DECISION - Information on all LLTs to be presented in monthly LMPB, but appended when LMPB is held the same day as 'Combined steering group for BPO and Lipid Management and FH AHSN national programmes' meeting	Decision	Decision	
A0446	Lipid Management Programme Board meeting	14/10/22	MR	Explore the ability to compare data on the use of LLTs against HI demographic data	21/10/22	Closed	21/11 - Merged to A0446 due to duplication 11/11 - Action to be closed and transferred into Metrcis T&F Group.
A0447	Lipid Management Programme Board meeting	14/10/22	MR / GF	Consider additional research study being led by PW and the need to further engage AHSNs as key parties to this (further discussion and review to take place outside of LMPB / JSC)	31/10/22	Closed	31/10 - Raised at JSC meeting. MR update
A0448	Lipid Management Programme Board meeting	14/10/22	GF	Schedule meeting with Deputy Chief Scientific Officer to review provision of LDL tests from pathology labs / networks (e.g. to understand current service disposition). MR & SC to join meeting	26/01/23	Closed	02/03 – Action closed, survey completed and following on work will be reported against in due course 20/12 - Following meeting with AD, a survey of pathology networks will be undertaken to ascertain current practices in laboratories. JC is preparing the survey based on current best practice and members of the programme have been invited to meet Pathology Network Leads in January to update on work to date and introduce the survey. Deadline updated to reflect update 08/12 – Meeting with AD scheduled for 13 Dec. Confirm whether JM to join the meeting, or schedule a follow up 11/11 - GF - No update from AD, waiting on the response from the group AD chairs. GF to follow up (SC, MR, and GF in talks with JM, need to be joined up).
A0449	Lipid Management Programme Board meeting	14/10/22	MR	Schedule meeting with GF and HW to review role of CLG and the future arrangements for a clinical panel to support work on lipid management (reporting to both CPU and AHSN work programmes)	28/10/22	Closed	GF / MR update on meeting outputs in LMPB 11 Nov
A0450	Lipid Management Programme Board meeting	14/10/22	LC	Meet with JN and JC to confirm what is needed from the dashboard for future iterations	28/10/22	Closed	28/02 - Closed. First iteration of the dashboard was delivered with further dashboard development ongoing based on any newly requested content. JN and JC input received 09/12 - LC team to work towards updated dashboard to include inclisiran KPIs and data for all therapies (as is for inclisiran) and complete in Jan. 11/11 - Action to remain open. Discussions are ongoing around what can be added to the dashboard for future iterations.
A0485	Lipid Management Programme Board meeting	11/11/22	GF / HW	CPU - SD and KP will develop TOR, and the meeting series will be scheduled.	09/12/22	Open	05/04 - MR to chase 28/03 - Moved new governance group from LMPB 27/03 - AH emailed KP for an update on CAG/CLG ToR 08/12 - MR chased for terms of reference and is working with KP to progress outputs 11/11 - MR to follow up with SD, KP, and GF. 08/08 - GF: The new group co-chaired by HW and himself has yet to meet but a date was being looked for by CPU. 03/03 - Conversations have happened and a provisional date identified. Clinical Leadership Group proposals (with input from GF) with CPU comms and should be brought into programme of work
A0486	Lipid Management Programme Board meeting	11/11/22	JP	Heart UK to communicate with NICE around patient advice	09/12/22	Closed	08/12 - MR confirmed that JP has written to NICE, advising on the benefit of an absolute target from patient perspective 11/11 - MR to follow up with JP.
A0516	Lipid Management Programme Board meeting	09/12/22	SC / JS	Present quarterly updates around the on-the-ground progress of INHP, STF, and NLPWSS and focus on learnings up to date.	10/03/22	Closed	11/01 - Presented at JSC, 5 Jan 09/12 - Utilise existing meetings (CLOG, Community of Practice, etc.) to provide updates to the wider programme.
A0517	Lipid Management Programme Board meeting	09/12/22	SC / GF / SM	Escalate to JSC - Agree on a course of action following the latest developments in West of England's LMC.	30/01/23	Closed	02/03 – Action closed, JSC informed, ongoing activity includes some further meetings with NVS colleagues where warranted
A0544	Lipid Management Programme Board meeting	26/01/23	DECISION	DECISION: LMPB agreed to cancel both 10 February and 10 March LMPB meetings. The former as it is only two weeks after the meeting on 26 January, and the latter will be moved to 3 February to bridge the gap before reverting back to second Friday of the Month	Decision	Decision	
A0546	Lipid Management Programme Board meeting	26/01/23	SC	Share the draft evaluation plan (from Imperial College) with LMPB JSC members once developed	09/04/23	Open	30/03 - Following agreement of revised governance framework, LMPB is to be disbanded and a quarterly AHSN CVD Programme Board established. Current LMPB actions will transfer to JSC or PMO Group (including this action) 15/03 - Outline project spec with Imperial College London awaiting budget management / itemised costs quote 03/03 - Informal and early conversations underway at the moment, Adjust deadline from 09/03 02/02 - One of the suppliers (from NLPWSS) has had Imperial College London offer to evaluate their intervention. The programme (SC) is currently in discussion with Imperial College to do a wider evaluation piece across the entirety of NLPWSS. Informal conversation have been held with the programme agreeing to provide specifications to Imperial College for them to produce a draft evaluation plan and indicative cost.
A0566	Lipid Management Programme Board meeting	03/03/23	MR / AB	Update LMPB members once offers have made and accepted to successful CLF EOs	17/03/23	Open	23/03 - NU shared tracker with AH 20/03 – Post JSC meeting 27/03 15/03 - 12 AHSNs (1 project each) have been made an offer subject to contract: milestones, and payment schedules, in progress with NENC. CLF agreement in final review. AH to find out if NU has final tracker of offer of acceptance plus details of subject to satisfactory responses supplied
A0567	Lipid Management Programme Board meeting	03/03/23	LMPB members	Review Issues and Risks Logs based on whether the logs are comprehensive a) nothing missing or redundant, and b) entries inform the programme's management and mitigations are achievable and focus on progressing the programme.	10/03/23	Closed	30/03 - LMPB to be disbanded, action closed 28/03 - No comments sent to date
A0568	Lipid Management Programme Board meeting	03/03/23	MR / SC	Reach out to ex-Clinical Leadership Group members (via RK & GF) regarding statins intolerance pathway on NHSE site. To note, the pathway is up to date and does not need reviewing however, the website says differently (i.e. needs amending). CLG members to provide formal response for a new pathway review date	10/03/23	Closed	09/03 - Close. Passed on to HW as chair of group that developed it and will address issue 08/03 - GF: CLG had no involvement in the intolerance pathway and not clear on who owns the document (post meeting note - was developed by the AAC/NICE group chaired by HW, however this group no longer exists)